Meditation in Inflammatory Dermatosis

NCT ID: NCT05500794

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-15

Study Completion Date

2026-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world. Although the physiopathological mechanisms are not yet clearly defined, these inflammatory dermatoses involve an interaction between the immune system and the epidermal cells, severe skin inflammation and often very intense pruritus. The objectives of an effective management should be to treat lesions in order to reduce them, but also to reduce itching and allow the patients to accept and cope with their pathology, without neglecting an improvement in the "Dermatology Life Quality Index" (DLQI) and in the psychological state, sometimes depressive, of the patient. Itching is defined as "a feeling that needs to be scratched urgently" and can cause significant distress along with pain. It severely impacts the quality of life and the quality of sleep. Chronic itching is associated with increased stress, anxiety, and other mood disorders. In turn, stress and anxiety exacerbate the itching, leading to a vicious cycle of pruritus - scratching that affects patient behavior (excessive scratching) and worsens disease prognosis and quality of life. Much research over the past few decades has demonstrated the effect of mindfulness meditation on emotional and cognitive responsiveness, cognitive flexibility, rumination, self-compassion and mindfulness, but also on acute pain, anxiety, stress, depression, cardiovascular disease, eating disorders, cancer and cognitive loss with age. Several studies have shown the impact of mindfulness on brain function and immunity, with evidence for the association between mindfulness and changes in the levels of markers characteristic of immune system activity and inflammation, known to be increased in psoriasis or atopic dermatitis. The objective is to evaluate the effect of mental training in the regulation of stress and emotions through mindfulness meditation in patients with moderate, itchy atopic dermatitis or psoriasis, not treated with systemic agents (e.g.: biotherapies). This project is based on the premise that mental training in the regulation of stress and emotions through meditation would reduce the effects of the infernal itch-scratch cycle, alleviating pruritus, thus improving the well-being and mental health of patients while reducing their inflammatory skin lesions and limiting the appearance of new lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis Psoriasis Pruritus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MBSR (Mindfulness-Based Stress Reduction) group

MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.

Group Type EXPERIMENTAL

MBSR (Mindfulness-Based Stress Reduction)

Intervention Type OTHER

MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.

In each weekly session, the instructor creates a supportive environment in which:

* Guided meditation practices;
* Mindfulness stretching and yoga;
* Reflection and group discussion periods aimed at promoting mindfulness in daily life;
* Practice instructions and opportunity to ask questions;
* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.

Audio recordings and a manual are provided to support personal practice

Standard group

No intervention in this group which will be followed according to the standard care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MBSR (Mindfulness-Based Stress Reduction)

MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.

In each weekly session, the instructor creates a supportive environment in which:

* Guided meditation practices;
* Mindfulness stretching and yoga;
* Reflection and group discussion periods aimed at promoting mindfulness in daily life;
* Practice instructions and opportunity to ask questions;
* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.

Audio recordings and a manual are provided to support personal practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 years old or older
* With health insurance coverage
* Significant pruritus defined by a Visual Analogical Scale (VAS) pruritus ≥ 4
* Patient with plaque psoriasis

* Without joint involvement
* Mild to moderate severity (PASI\>10)
* DLQI \> 10

OR Patient with atopic dermatitis:

* Mild to moderate severity (SCORAD\>10)
* DLQI \> 10
* Diagnosis according to Hanifin and Raijka criteria

* Patient in a stable psychological state
* French langage spoken

Exclusion Criteria

* Current systemic treatment or treatment discontinued within the last month
* Psychiatric illnesses diagnosed according to the DSM-5 or ICD-10 international criteria of psychotic disorder, severe anxiety disorder, depressive disorder with a current depressive episode of severe intensity, bipolar disorder with a current depressive or manic episode
* Taking psychotropic or neuroleptic treatments
* Participation in another interventional research study or being in the exclusion period at the end of a previous study, if applicable
* Patient under AME
Minimum Eligible Age

18 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Saint-Louis

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Charles CASSIUS, Dr

Role: CONTACT

+331.42.38.50.49

Jérôme Lambert, Pr

Role: CONTACT

+33142499742

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Charles CASSIUS

Role: primary

+331.42.38.50.49

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP211191

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.